Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Bicara’s bispecific antibody treatment on top of Keytruda led to tumor shrinkage in about half of patients with head and neck cancer that has relapsed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23

Lei Lei Wu

News Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA gives AbbVie accelerated approval for antibody-drug conjugate in lung cancer

AbbVie doubles down on siRNA with $335M upfront bet on ADARx

RFK Jr. defends HHS staff cuts, reorganization plans in House, Senate hearings

GSK to pay $1.2B upfront to snag Boston Pharma’s mid-stage MASH hope

RFK Jr. says his opinions of vaccines are ‘irrelevant.’ Former FDA chief Califf disagrees

Novo turns to Septerna for oral obesity medicines in deal worth up to $2.2B

Ear­ly da­ta show Bicara’s bis­pe­cif­ic helps shrink head and neck can­cers when com­bined with Keytru­da: #AS­CO23

News Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Early data show Bicara’s bispecific helps shrink head and neck cancers when combined with Keytruda: #ASCO23